{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.75","value":"-1.9"},{"groupId":"OG001","spread":"22.63","value":"-2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.74","value":"-5.1"},{"groupId":"OG001","spread":"23.54","value":"-2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.76","value":"-8.3"},{"groupId":"OG001","spread":"24.56","value":"-6.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.33","value":"-6.9"},{"groupId":"OG001","spread":"24.22","value":"-6.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"Cycle 9, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.58","value":"-0.5"},{"groupId":"OG001","spread":"25.38","value":"-5.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"title":"Cycle 11, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.05","value":"-1.0"},{"groupId":"OG001","spread":"22.24","value":"-1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"title":"Cycle 13, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.09","value":"-4.9"},{"groupId":"OG001","spread":"23.56","value":"0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"Cycle 15, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.91","value":"-5.1"},{"groupId":"OG001","spread":"21.55","value":"-7.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Cycle 17, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.51","value":"-1.3"},{"groupId":"OG001","spread":"26.09","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Cycle 19, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.16","value":"-6.6"},{"groupId":"OG001","spread":"20.01","value":"-5.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 21, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.20","value":"-2.9"},{"groupId":"OG001","spread":"22.99","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Cycle 23, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.29","value":"-4.7"},{"groupId":"OG001","spread":"24.68","value":"-4.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 25, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.46","value":"-9.0"},{"groupId":"OG001","spread":"26.70","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Cycle 27, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.67","value":"-6.9"},{"groupId":"OG001","spread":"26.33","value":"-1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Cycle 29, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.48","value":"-4.8"},{"groupId":"OG001","spread":"35.36","value":"5.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 31, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.22","value":"-7.7"},{"groupId":"OG001","spread":"22.79","value":"-7.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Cycle 33, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.03","value":"-3.8"},{"groupId":"OG001","spread":"29.23","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Cycle 35, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.86","value":"-13.7"},{"groupId":"OG001","spread":"12.50","value":"10.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 37, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.05","value":"-9.3"},{"groupId":"OG001","spread":"0.00","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 39, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.47","value":"-11.0"},{"groupId":"OG001","spread":"8.33","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 41, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.95","value":"2.0"},{"groupId":"OG001","spread":"23.57","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 43, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.75","value":"-1.7"},{"groupId":"OG001","spread":"5.89","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 45, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.95","value":"10.4"},{"groupId":"OG001","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 47, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.40","value":"-8.1"},{"groupId":"OG001","spread":"28.50","value":"-6.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"Final visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"description":"The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Global Health Status/Quality of Life scale, participants rate two items on a seven point scale, with 1 as \"very poor\" and 7 as \"excellent.\" The Global Health Status/Quality of Life scale ranges from 0 to 100 and was calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high score for the global health status/QoL represents a high QoL. Positive changes from baseline indicate improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23","id":"OG000","title":"Venetoclax + Bortezomib and Dexamethasone"},{"description":"Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \\& 23","id":"OG001","title":"Placebo + Bortezomib and Dexamethasone"}],"paramType":"MEAN","populationDescription":"Intent-To-Treat (ITT) analysis set: all randomized participants, analyzed by treatment group assignment given at the time of randomization; participants who have both baseline and post-baseline values are included in the analysis at each visit","reportingStatus":"POSTED","timeFrame":"Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment","title":"Mean Change From Baseline in Global Health Status/Quality of Life Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)","type":"SECONDARY","unitOfMeasure":"units on a scale"}